LobbyingCrispr Therapeutics lobbying by quarter
Crispr Therapeutics's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.
Crispr Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $140K | 2 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$55K · 2 reports
- Medicare and Medicaid$55K · 2 reports
- Medical research and clinical labs$30K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- Health & Human Services, Dept of (HHS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseCrispr Therapeutics | $90K | 15 quarters |
| Todd Strategy Group | $50K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ctr. - Medicare & Medicaid | Q4 2022 |
| PAUL EDATTEL | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg | Q4 2022 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/04for Q2 | In-house | Under $5,000 |
| 05/04for Q1 | In-house | Under $5,000 |
| 02/07for Q4 2025 | In-house | Under $5,000 |
| 25/11/07for Q3 2025 | In-house | Under $5,000 |
| 25/08/05for Q2 2025 | In-house | Under $5,000 |
| 25/05/06for Q1 2025 | In-house | Under $5,000 |
| 25/02/05for Q4 2024 | In-house | Under $5,000 |
| 24/11/07for Q3 2024 | In-house | Under $5,000 |
| 24/08/12for Q2 2024 | In-house | Under $5,000 |
| 24/05/15for Q1 2024 | In-house | Under $5,000 |
| 24/02/06for Q4 2023 | In-house | Under $5,000 |
| 23/11/22for Q3 2023 | In-house | Under $5,000 |
| 23/08/07for Q2 2023 | In-house | Under $5,000 |
| 23/05/31for Q1 2023 | In-house | Under $5,000 |
| 23/04/19for Q4 2022 | Todd Strategy Group | $50K |
| 23/01/20for Q4 2022 | Todd Strategy Group | $50K |
| 23/01/05for Q4 2022 | In-house | $90K |